|
|
|
||
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange
on which registered
|
||
|
|
|
||
|
|
|
Exhibit
No.
|
Description
|
|
Company’s audited consolidated financial statements as of December 31, 2022 and 2021 and for each of the three years in the period
ended December 31, 2022
|
||
Company’s Management’s Discussion and Analysis Of Financial Condition And Results Of Operations
|
||
101.INS | XBRL Instance Document—the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |
101.SCH |
Inline XBRL Taxonomy Extension Schema Document
|
|
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |
101.PRE |
Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
104
|
Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).
|
AMERICAN ONCOLOGY NETWORK, INC.
|
||
Date: November 27, 2023
|
By:
|
/s/ David Gould
|
Name:
|
David Gould
|
|
Title:
|
Chief Financial Officer
|
|
| |
As of December 31,
|
|||
|
| |
2022
|
| |
2021
|
Assets
|
| |
|
| |
|
Current assets
|
| |
|
| |
|
Cash and cash equivalents
|
| |
$
|
| |
$
|
Short-term marketable securities
|
| |
|
| |
|
Restricted cash
|
| |
|
| |
|
Patient accounts receivable, net
|
| |
|
| |
|
Inventories
|
| |
|
| |
|
Other receivables
|
| |
|
| |
|
Prepaids expenses and other current assets
|
| |
|
| |
|
|
| |
|
| |
|
Total current assets
|
| |
|
| |
|
Property and equipment, net
|
| |
|
| |
|
Operating right of use assets, net(1)
|
| |
|
| |
|
|
| |
|
| |
|
Other assets
|
| |
|
| |
|
Goodwill and intangibles, net
|
| |
|
| |
|
Total assets
|
| |
$
|
| |
$
|
Liabilities and Members’ Equity
|
| |
|
| |
|
Current liabilities
|
| |
|
| |
|
Accounts payable(2)
|
| |
$
|
| |
$
|
Accrued compensation related costs
|
| |
|
| |
|
Accrued other
|
| |
|
| |
|
Medicare advance payment
|
| |
|
| |
|
Current portion operating lease liability(3)
|
| |
|
| |
|
Total current liabilities
|
| |
|
| |
|
Commitments and contingencies (Note 16)
|
| |
|
| |
|
Long-term portion operating lease liability(4)
|
| |
|
| |
|
Long-term debt, net
|
| |
|
| |
|
Other long-term liabilities
|
| |
|
| |
|
Total liabilities
|
| |
|
| |
|
Stockholders’ equity
|
| |
|
| |
|
Class A units;
|
| |
|
| |
|
Class A-1 units;
|
| |
|
| |
|
Class B units;
|
| |
|
| |
|
Accumulated other comprehensive loss
|
| |
(
|
| |
|
Retained earnings
|
| |
|
| |
|
Total members’ equity
|
| |
|
| |
|
Total liabilities and members’ equity
|
| |
$
|
| |
$
|
(1)
|
—
|
(2)
|
—
|
(3)
|
—
|
(4)
|
—
|
|
| |
Year Ended December 31,
|
||||||
|
| |
2022
|
| |
2021
|
| |
2020
|
Revenue
|
| |
|
| |
|
| |
|
Patient service revenue, net
|
| |
$
|
| |
$
|
| |
$
|
HHS grant income
|
| |
|
| |
|
| |
|
Other revenue
|
| |
|
| |
|
| |
|
Total revenue
|
| |
|
| |
|
| |
|
Costs and expenses
|
| |
|
| |
|
| |
|
Cost of revenue(1)(2)
|
| |
|
| |
|
| |
|
General and administrative expenses
|
| |
|
| |
|
| |
|
Total costs and expenses
|
| |
|
| |
|
| |
|
Income from operations
|
| |
|
| |
|
| |
|
Other income (expense)
|
| |
|
| |
|
| |
|
Interest expense
|
| |
(
|
| |
(
|
| |
(
|
Interest income
|
| |
|
| |
|
| |
|
Other income, net
|
| |
|
| |
|
| |
|
Income before income taxes
|
| |
|
| |
|
| |
|
Income tax expense (benefit)
|
| |
|
| |
|
| |
(
|
Net income (loss) before noncontrolling interest
|
| |
$
|
| |
$(
|
| |
$
|
Net income (loss) attributable to Legacy AON Shareholders
prior to the reverse recapitalization
|
| |
$
|
| |
$(
|
| |
$
|
Net loss attributable to Class A Common Stockholders
|
| |
$
|
| |
$
|
| |
$
|
Earnings (loss) per Class A Common Stock:
|
| |
|
| |
|
| |
|
basic and diluted
|
| |
$
|
| |
$
|
| |
$
|
Weighted average Class A Common Stock outstanding:
|
| |
|
| |
|
| |
|
basic and diluted
|
| |
|
| |
|
| |
|
Other comprehensive loss:
|
| |
|
| |
|
| |
|
Unrealized losses on marketable securities
|
| |
(
|
| |
|
| |
|
Other comprehensive loss
|
| |
(
|
| |
|
| |
|
Comprehensive income (loss)
|
| |
$
|
| |
$(
|
| |
$
|
(1)
|
|
(2)
|
|
|
| |
Class A
|
| |
Class A-1
|
| |
Class B
Units
|
| |
Class B
$
|
| |
Accumulated
Other
Comprehensive
Loss
|
| |
Retained
Earnings
|
| |
Total
Members’
Equity
|
||||||
|
| |
Units
|
| |
$
|
| |
Units
|
| |
$
|
| ||||||||||||||
Balances at December 31, 2019
|
| |
|
| |
$
|
| |
|
| |
$
|
| |
|
| |
$
|
| |
$
|
| |
$
|
| |
$
|
Issuance of Class A-1 units, net of issuance costs
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
Net income
|
| |
—
|
| |
|
| |
—
|
| |
|
| |
—
|
| |
|
| |
|
| |
|
| |
|
Equity-based compensation
|
| |
—
|
| |
|
| |
—
|
| |
|
| |
—
|
| |
|
| |
|
| |
|
| |
|
Balances at December 31, 2020
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
Net income
|
| |
—
|
| |
|
| |
—
|
| |
|
| |
—
|
| |
|
| |
|
| |
(
|
| |
(
|
Equity-based compensation
|
| |
—
|
| |
|
| |
—
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
Balances at December 31, 2021
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
Net income
|
| |
—
|
| |
|
| |
—
|
| |
|
| |
—
|
| |
|
| |
|
| |
|
| |
|
Other comprehensive loss
|
| |
—
|
| |
|
| |
—
|
| |
|
| |
—
|
| |
|
| |
(
|
| |
|
| |
(
|
Balances at December 31, 2022
|
| |
|
| |
$
|
| |
|
| |
$
|
| |
|
| |
$
|
| |
$(
|
| |
$
|
| |
$
|
|
| |
Year Ended December 31,
|
||||||
|
| |
2022
|
| |
2021
|
| |
2020
|
Cash flows from operating activities
|
| |
|
| |
|
| |
|
Net income (loss)
|
| |
$
|
| |
$(
|
| |
$
|
Adjustments to reconcile net income (loss) to net cash (used
in) provided by operating activities
|
| |
|
| |
|
| |
|
Depreciation and amortization
|
| |
|
| |
|
| |
|
Amortization of debt issuance costs
|
| |
|
| |
|
| |
|
Amortization of right-of-use assets(1)
|
| |
|
| |
|
| |
|
Loss on extinguishment of debt financing costs
|
| |
|
| |
|
| |
|
Equity-based compensation
|
| |
|
| |
|
| |
|
Deferred income taxes
|
| |
|
| |
|
| |
(
|
Gain on sale of equipment
|
| |
(
|
| |
(
|
| |
|
Deferred rent
|
| |
|
| |
|
| |
|
Changes in operating assets and liabilities:
|
| |
|
| |
|
| |
|
Patient accounts receivable, net
|
| |
(
|
| |
(
|
| |
(
|
Inventories(2)
|
| |
(
|
| |
(
|
| |
(
|
Prepaid expenses and other current assets
|
| |
|
| |
(
|
| |
(
|
Other receivables
|
| |
(
|
| |
(
|
| |
(
|
Other assets
|
| |
(
|
| |
(
|
| |
(
|
Accounts payable(3)
|
| |
|
| |
|
| |
|
Accrued compensation related costs
|
| |
(
|
| |
|
| |
|
Accrued other
|
| |
|
| |
|
| |
|
Operating lease liability(4)
|
| |
(
|
| |
|
| |
|
Medicare advance payment
|
| |
(
|
| |
(
|
| |
|
Other long-term liabilities
|
| |
|
| |
|
| |
|
Net cash (used in) provided by operating activities
|
| |
(
|
| |
(
|
| |
|
Cash flows from investing activities
|
| |
|
| |
|
| |
|
Purchases of property and equipment
|
| |
(
|
| |
(
|
| |
(
|
Disposals of property and equipment
|
| |
|
| |
|
| |
|
Purchase of marketable securities
|
| |
(
|
| |
|
| |
|
Proceeds from sales of marketable securities
|
| |
|
| |
|
| |
|
Acquisition of physician practices
|
| |
(
|
| |
(
|
| |
(
|
Issuance of notes receivable — related parties
|
| |
(
|
| |
(
|
| |
(
|
Collections on notes receivable — related parties
|
| |
|
| |
|
| |
|
Net cash used in investing activities
|
| |
(
|
| |
(
|
| |
(
|
Cash flows from financing activities
|
| |
|
| |
|
| |
|
Repayments of revolving line of credit
|
| |
|
| |
(
|
| |
(
|
Borrowings on long-term debt
|
| |
|
| |
|
| |
|
Repayments of long-term debt
|
| |
|
| |
(
|
| |
(
|
Issuance of class A-1 units, net of issuance costs
|
| |
|
| |
|
| |
|
Cash paid for deferred offering costs
|
| |
(
|
| |
|
| |
|
Repayments on finance and capital leases
|
| |
(
|
| |
(
|
| |
|
Cash paid for debt financing costs
|
| |
(
|
| |
(
|
| |
(
|
Net cash provided by financing activities
|
| |
|
| |
|
| |
|
Net (decrease) increase in cash and cash equivalents and
restricted cash
|
| |
(
|
| |
(
|
| |
|
|
| |
Year Ended December 31,
|
||||||
|
| |
2022
|
| |
2021
|
| |
2020
|
Cash, cash equivalents and restricted cash
|
| |
|
| |
|
| |
|
Beginning of year
|
| |
|
| |
|
| |
|
End of year
|
| |
$
|
| |
$
|
| |
$
|
Supplemental consolidated cash flow information
|
| |
|
| |
|
| |
|
Cash paid for interest
|
| |
$
|
| |
$
|
| |
$
|
Cash paid for income taxes
|
| |
|
| |
|
| |
|
Supplemental noncash investing and financing activities
|
| |
|
| |
|
| |
|
Changes in accounts payable for capital additions to
property and equipment
|
| |
|
| |
|
| |
|
Assumed capital lease liabilities in acquisition of physician practice
|
| |
|
| |
|
| |
|
Reduction of notes receivable as consideration for purchase
of physician practice assets
|
| |
|
| |
|
| |
|
Note payable for acquisition of physician practice
|
| |
|
| |
|
| |
|
Payables for deferred offering costs
|
| |
|
| |
|
| |
|
Disposal of property and equipment in exchange for reduction
in finance lease liability
|
| |
|
| |
|
| |
|
(1)
|
|
(2)
|
|
(3)
|
|
(4)
|
|
2020
|
| |
2021
|
| |
2022
|
||||||||||||||||||
|
| |
State
|
| |
Effective
Date
|
| |
|
| |
State
|
| |
Effective
Date
|
| |
|
| |
State
|
| |
Effective
Date
|
Location 12
|
| |
North
Carolina
|
| |
|
| |
Location 18
|
| |
Maryland
|
| |
|
| |
Location 23
|
| |
Arizona
|
| |
|
Location 13
|
| |
Maryland
|
| |
|
| |
Location 19
|
| |
Arizona
|
| |
|
| |
Location 24
|
| |
Georgia(a)
|
| |
|
Location 14
|
| |
Virginia
|
| |
|
| |
Location 20
|
| |
Washington
|
| |
|
| |
Location 25
|
| |
Louisiana(a)
|
| |
|
Location 15
|
| |
Michigan
|
| |
|
| |
Location 21
|
| |
Georgia(a)
|
| |
|
| |
Location 26
|
| |
Georgia(a)
|
| |
|
Location 16
|
| |
Washington
|
| |
|
| |
Location 22
|
| |
Arizona
|
| |
|
| |
Location 27
|
| |
Georgia(a)
|
| |
|
Location 17
|
| |
Georgia and
South
Carolina
|
| |
|
| |
|
| |
|
| |
|
| |
Location 28
|
| |
Georgia(a)
|
| |
|
(a)
|
|
|
| |
As of December 31,
|
|||
|
| |
2022
|
| |
2021
|
Cash and cash equivalents
|
| |
$
|
| |
$
|
Restricted cash
|
| |
|
| |
|
Total cash, cash equivalents and restricted cash shown in the statements of cash
flow
|
| |
$
|
| |
$
|
|
| |
As of December 31,
|
|||
|
| |
2022
|
| |
2021
|
Medicare
|
| |
|
| |
|
Managed Medicare
|
| |
|
| |
|
Other Commercial
|
| |
|
| |
|
BCBS
|
| |
|
| |
|
Managed Medicaid
|
| |
|
| |
|
Other
|
| |
|
| |
|
|
| |
|
| |
|
Leasehold improvements
|
| |
|
Furniture, fixtures and equipment
|
| |
|
Medical equipment
|
| |
|
Computer equipment
|
| |
|
Signs
|
| |
|
Automobiles
|
| |
|
Software
|
| |
|
Level 1
|
Inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.
|
Level 2
|
Inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived
valuations in which all significant inputs are observable for substantially the full term of the asset or liability.
|
Level 3
|
Inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability.
|
|
| |
As of December 31,
|
|||
Assets
|
| |
2022
|
| |
2021
|
Cash and cash equivalents
|
| |
$
|
| |
$
|
Accounts receivable
|
| |
|
| |
|
Inventories
|
| |
|
| |
|
Property and equipment, net
|
| |
|
| |
|
Prepaid expenses and other current assets
|
| |
|
| |
|
Goodwill and intangibles, net
|
| |
|
| |
|
Other receivables
|
| |
|
| |
|
Other assets
|
| |
|
| |
|
Total assets
|
| |
$
|
| |
$
|
|
| |
As of December 31,
|
|||
Liabilities
|
| |
2022
|
| |
2021
|
Accounts payable
|
| |
$
|
| |
$
|
Accrued compensation and benefits
|
| |
|
| |
|
Accrued other
|
| |
|
| |
|
Medicare advance payment
|
| |
|
| |
|
Other long-term liabilities
|
| |
|
| |
|
Due to AON and subsidiaries, net
|
| |
|
| |
|
Total liabilities
|
| |
$
|
| |
$
|
|
| |
2021
Acquired
Locations
|
Purchase consideration
|
| |
|
Cash transferred upon closing
|
| |
$
|
Assumed capital lease liabilities
|
| |
|
Total consideration transferred
|
| |
|
Net assets acquired
|
| |
|
Inventories
|
| |
|
Other assets
|
| |
|
Property and equipment
|
| |
|
Total net assets acquired
|
| |
|
Amount assigned to goodwill
|
| |
$
|
|
| |
2020
Acquired
Locations
|
Purchase consideration
|
| |
|
Cash transferred upon closing
|
| |
$
|
Issuance of note payable
|
| |
|
Non-cash settlement
|
| |
|
Total consideration transferred
|
| |
|
Net assets acquired
|
| |
|
Inventories
|
| |
|
Property and equipment
|
| |
|
Prepaids
|
| |
|
Total net assets acquired
|
| |
|
Amount assigned to goodwill
|
| |
$
|
|
| |
Pro Forma
|
||||||
|
| |
Year Ended December 31,
|
||||||
|
| |
2022
|
| |
2021
|
| |
2020
|
Revenue
|
| |
$
|
| |
$
|
| |
$
|
Net income
|
| |
$
|
| |
$
|
| |
$
|
|
| |
As of December 31, 2022
|
|||||||||
|
| |
Amortized Cost
|
| |
Gross
Unrealized
Gains
|
| |
Gross
Unrealized
Losses
|
| |
Estimated
Fair
Value
|
Cash equivalents(1)
|
| |
|
| |
|
| |
|
| |
|
Level 1:
|
| |
|
| |
|
| |
|
| |
|
Money market funds
|
| |
$
|
| |
$
|
| |
$
|
| |
$
|
Marketable securities
|
| |
|
| |
|
| |
|
| |
|
Level 2:
|
| |
|
| |
|
| |
|
| |
|
Corporate bonds
|
| |
|
| |
|
| |
(
|
| |
|
U.S. Treasury securities
|
| |
|
| |
|
| |
(
|
| |
|
Level 2 total
|
| |
|
| |
|
| |
(
|
| |
|
Total
|
| |
$
|
| |
$
|
| |
$(
|
| |
$
|
(1)
|
|
|
| |
As of December 31, 2022
|
||||||
|
| |
Corporate
Bonds
|
| |
U.S. Treasury
Securities
|
| |
Total
|
Due within one year
|
| |
$
|
| |
$
|
| |
$
|
Due within one to five years
|
| |
|
| |
|
| |
|
Total
|
| |
$
|
| |
$
|
| |
$
|
|
| |
As of December 31,
|
|||
|
| |
2022
|
| |
2021
|
Intravenous drugs
|
| |
$
|
| |
$
|
Oral pharmaceuticals
|
| |
|
| |
|
Total inventories
|
| |
$
|
| |
$
|
|
| |
As of December 31,
|
|||
|
| |
2022
|
| |
2021
|
Rebates receivable
|
| |
$
|
| |
$
|
Other
|
| |
|
| |
|
Total other receivables
|
| |
$
|
| |
$
|
|
| |
As of December 31,
|
|||
|
| |
2022
|
| |
2021
|
Leasehold improvements
|
| |
$
|
| |
$
|
Furniture, fixtures and equipment
|
| |
|
| |
|
Medical equipment
|
| |
|
| |
|
Computer equipment
|
| |
|
| |
|
Signs
|
| |
|
| |
|
Automobiles
|
| |
|
| |
|
Software
|
| |
|
| |
|
Construction-in-progress
|
| |
|
| |
|
|
| |
|
| |
|
Accumulated depreciation and amortization
|
| |
(
|
| |
(
|
Property and equipment, net
|
| |
$
|
| |
$
|
|
| |
As of December 31,
|
|||
|
| |
2022
|
| |
2021
|
Refund liability
|
| |
$
|
| |
$
|
Deferred social security taxes – COVID
|
| |
|
| |
|
Current portion of finance lease liability
|
| |
|
| |
|
Other
|
| |
|
| |
|
Total accrued other
|
| |
$
|
| |
$
|
|
| |
As of December 31,
|
|||
|
| |
2022
|
| |
2021
|
PNC Facility
|
| |
$
|
| |
$
|
Total
|
| |
|
| |
|
Unamortized debt issuance costs
|
| |
(
|
| |
(
|
Total debt
|
| |
$
|
| |
$
|
|
| |
Year Ended December 31,
|
||||||
|
| |
2022
|
| |
2021
|
| |
2020
|
Current
|
| |
|
| |
|
| |
|
Federal
|
| |
$
|
| |
$(
|
| |
$
|
State
|
| |
|
| |
(
|
| |
|
|
| |
|
| |
(
|
| |
|
Deferred
|
| |
|
| |
|
| |
|
Federal
|
| |
|
| |
|
| |
(
|
State
|
| |
|
| |
|
| |
(
|
|
| |
|
| |
|
| |
(
|
Total income tax expense (benefit)
|
| |
$
|
| |
$
|
| |
$(
|
|
| |
Year Ended December 31,
|
||||||
|
| |
2022
|
| |
2021
|
| |
2020
|
Federal statutory income tax rate
|
| |
|
| |
|
| |
|
State taxes, net of federal benefit
|
| |
(
|
| |
(
|
| |
(
|
State rate change
|
| |
(
|
| |
(
|
| |
|
Other
|
| |
(
|
| |
|
| |
|
Nontaxable passthrough LLC income
|
| |
(
|
| |
(
|
| |
(
|
Increase in valuation allowance
|
| |
|
| |
|
| |
|
Effective tax rate
|
| |
|
| |
|
| |
(
|
|
| |
As of December 31,
|
|||
|
| |
2022
|
| |
2021
|
Deferred tax assets
|
| |
|
| |
|
Net operating loss carryforwards
|
| |
$
|
| |
$
|
Accrued expenses
|
| |
|
| |
|
Deferred tax assets
|
| |
|
| |
|
Valuation allowance
|
| |
(
|
| |
(
|
Net deferred tax asset
|
| |
|
| |
|
Deferred tax liabilities
|
| |
|
| |
|
Prepaid expenses
|
| |
|
| |
|
Accounting method change
|
| |
|
| |
|
Fixed assets
|
| |
|
| |
|
Deferred tax liabilities
|
| |
|
| |
|
Net deferred tax asset
|
| |
$
|
| |
$
|
|
| |
As of December 31,
|
| |
Original
Principal
|
| |
Issue
Date
|
| |
Maturity
Date
|
|||
|
| |
2022
|
| |
2021
|
| ||||||||
Notes receivable
|
| |
|
| |
|
| |
|
| |
|
| |
|
Note 2
|
| |
$
|
| |
$
|
| |
$
|
| |
|
| |
|
Note 3
|
| |
|
| |
|
| |
|
| |
|
| |
|
Note 4
|
| |
|
| |
|
| |
|
| |
|
| |
|
Note 6
|
| |
|
| |
|
| |
|
| |
|
| |
|
Note 8
|
| |
|
| |
|
| |
|
| |
|
| |
|
Note 9
|
| |
|
| |
|
| |
|
| |
|
| |
|
Total notes receivables
|
| |
|
| |
|
| |
|
| |
|
| |
|
Less: Current portion of notes receivable
|
| |
(
|
| |
(
|
| |
|
| |
|
| |
|
Notes receivable, less current portion
|
| |
$
|
| |
$
|
| |
|
| |
|
| |
|
Assets
|
| |
|
|
| |
$
|
Finance lease right-of-use assets, net (included in
) |
| |
|
Total right-of-use assets
|
| |
$
|
Liabilities
|
| |
|
Current
|
| |
|
Current portion of
|
| |
$
|
Current portion of finance lease liabilities (included in
) |
| |
|
Long-term
|
| |
|
Long-term
|
| |
|
Long-term finance lease liabilities (included in
) |
| |
|
Total lease liabilities
|
| |
$
|
Operating lease costs
|
| |
$
|
Finance lease costs
|
| |
|
Amortization of finance lease right-of-use assets
|
| |
|
Interest on finance lease liabilities (included in interest expense)
|
| |
|
Variable lease costs
|
| |
|
Total lease costs
|
| |
$
|
|
| |
Operating Leases
|
| |
Finance Leases
|
2023
|
| |
$
|
| |
$
|
2024
|
| |
|
| |
|
2025
|
| |
|
| |
|
2026
|
| |
|
| |
|
2027
|
| |
|
| |
|
Thereafter
|
| |
|
| |
|
Total lease payments
|
| |
|
| |
|
Less: amount representing interest
|
| |
(
|
| |
(
|
Present value of lease liabilities
|
| |
|
| |
|
Less: current portion of lease liabilities
|
| |
(
|
| |
(
|
Long-term lease liabilities, net of current portion
|
| |
$
|
| |
$
|
Cash paid for amounts included in the measurement of lease liabilities:
|
| |
|
Operating cash flows from operating leases
|
| |
$
|
Operating cash flows from finance leases
|
| |
|
Financing cash flows from finance leases
|
| |
|
ROU assets obtained in exchange for new operating lease liabilities
|
| |
|
•
|
Total patient encounters which include initial consultations and treatments, new patient encounters, recurring patient
encounters and treatments, and cancer vs non cancer patients.
|
•
|
Patient referrals which are also an important driver of patient service revenue; we manage the referral pipeline locally
through the coordinated efforts of our physician liaisons working with our physicians to market our practices by visiting referral sources such as, primary care providers and other medical specialties.
|
•
|
The cost of prescription drugs used in our treatment plans which include both intravenous and oral oncolytics. The management
of these costs are a critical component of our business as it is our single largest expense. We manage this cost by strategic volume purchases and continuously evaluating the most clinically effective drug for cancer type through our
Pharmaceutical and Therapeutics Committee.
|
•
|
Clinical compensation and benefits, including non-medical personnel, represent our second largest operating expense. These
costs are impacted by both micro and macro-economic factors as well as local
|
•
|
We lease all of our facilities, therefore real-estate costs are a significant component of our operating costs. We continuously
monitor local and national real estate conditions to actively manage our exposure to fluctuating occupancy costs.
|
|
| |
Three Months Ended
September 30,
|
| |
Change
|
| |
Nine Months Ended
September 30,
|
| |
Change
|
||||||||||||
(dollars in thousands)
|
| |
2023
|
| |
2022
|
| |
$
|
| |
%
|
| |
2023
|
| |
2022
|
| |
$
|
| |
%
|
Patient service revenue, net
|
| |
$332,195
|
| |
$293,612
|
| |
$38,583
|
| |
13.1%
|
| |
$945,681
|
| |
$840,507
|
| |
$105,174
|
| |
12.5%
|
Other revenue
|
| |
4,110
|
| |
3,712
|
| |
398
|
| |
10.7%
|
| |
9,322
|
| |
8,765
|
| |
557
|
| |
6.4%
|
Total revenue
|
| |
$336,305
|
| |
$297,324
|
| |
$38,981
|
| |
13.1%
|
| |
$955,003
|
| |
$849,272
|
| |
$105,731
|
| |
12.4%
|
|
| |
Three Months Ended
September 30,
|
| |
Change
|
| |
Nine Months Ended
September 30,
|
| |
Change
|
||||||||||||
(dollars in thousands)
|
| |
2023
|
| |
2022
|
| |
$
|
| |
%
|
| |
2023
|
| |
2022
|
| |
$
|
| |
%
|
Cost of revenue
|
| |
$310,894
|
| |
$267,647
|
| |
$43,247
|
| |
16.2%
|
| |
$880,827
|
| |
$780,658
|
| |
$100,169
|
| |
12.8%
|
General and administrative expenses
|
| |
25,199
|
| |
23,432
|
| |
1,767
|
| |
7.5%
|
| |
72,831
|
| |
66,155
|
| |
6,676
|
| |
10.1%
|
Transaction expenses
|
| |
24,603
|
| |
151
|
| |
24,452
|
| |
*
|
| |
29,886
|
| |
151
|
| |
29,735
|
| |
*
|
Total costs and expenses
|
| |
$360,696
|
| |
$291,230
|
| |
$69,466
|
| |
23.9%
|
| |
$983,544
|
| |
$846,964
|
| |
$136,580
|
| |
16.1%
|
*
|
— % not meaningful
|
|
| |
Three Months Ended
September 30,
|
| |
Change
|
| |
Nine Months Ended
September 30,
|
| |
Change
|
||||||||||||
(dollars in thousands)
|
| |
2023
|
| |
2022
|
| |
$
|
| |
%
|
| |
2023
|
| |
2022
|
| |
$
|
| |
%
|
Interest expense
|
| |
$(1,532)
|
| |
$(924)
|
| |
$(608)
|
| |
65.8%
|
| |
$(4,500)
|
| |
$(2,034)
|
| |
$(2,466)
|
| |
121.2%
|
Interest income
|
| |
373
|
| |
49
|
| |
324
|
| |
*
|
| |
499
|
| |
104
|
| |
395
|
| |
*
|
Other (expense) income, net
|
| |
(3,309)
|
| |
388
|
| |
(3,697)
|
| |
(952.8%)
|
| |
(7,689)
|
| |
849
|
| |
(8,538)
|
| |
(1005.7%)
|
Total other expense
|
| |
$(4,468)
|
| |
$(487)
|
| |
$(3,981)
|
| |
817.4%
|
| |
$(11,690)
|
| |
$(1,081)
|
| |
$(10,609)
|
| |
981.4%
|
*
|
— % not meaningful
|
|
| |
Three Months
Ended September 30,
|
| |
Change
|
| |
Nine Months Ended
September 30,
|
| |
Change
|
||||||||||||
(dollars in thousands)
|
| |
2023
|
| |
2022
|
| |
$
|
| |
%
|
| |
2023
|
| |
2022
|
| |
$
|
| |
%
|
Provision for income taxes
|
| |
$315
|
| |
$—
|
| |
$315
|
| |
*
|
| |
$315
|
| |
$—
|
| |
$315
|
| |
*
|
Effective tax rate
|
| |
(1.1)%
|
| |
—%
|
| |
|
| |
|
| |
(0.8)%
|
| |
—%
|
| |
|
| |
|
*
|
— % not meaningful
|
|
| |
Year ended December 31,
|
| |
Change
|
||||||
(dollars in thousands)
|
| |
2022
|
| |
2021
|
| |
$
|
| |
%
|
Patient service revenue, net
|
| |
$1,137,932
|
| |
$938,242
|
| |
$199,690
|
| |
21.3%
|
|
| |
Year ended December 31,
|
| |
Change
|
||||||
(dollars in thousands)
|
| |
2022
|
| |
2021
|
| |
$
|
| |
%
|
Other revenue
|
| |
11,738
|
| |
5,505
|
| |
$6,233
|
| |
113.2%
|
Total revenue
|
| |
$1,149,670
|
| |
$943,747
|
| |
$205,923
|
| |
21.8%
|
|
| |
Year ended December 31,
|
| |
Change
|
||||||
(dollars in thousands)
|
| |
2022
|
| |
2021
|
| |
$
|
| |
%
|
Cost of revenue
|
| |
$1,054,217
|
| |
$865,788
|
| |
$188,429
|
| |
21.8%
|
General and administrative expenses
|
| |
89,887
|
| |
77,048
|
| |
12,839
|
| |
16.7%
|
Total costs and expenses
|
| |
$1,144,104
|
| |
$942,836
|
| |
$201,268
|
| |
21.3%
|
|
| |
Year ended December 31,
|
| |
Change
|
||||||
(dollars in thousands)
|
| |
2022
|
| |
2021
|
| |
$
|
| |
%
|
Interest expense
|
| |
$(3,417)
|
| |
$(1,419)
|
| |
$(1,998)
|
| |
140.8%
|
Interest income
|
| |
151
|
| |
127
|
| |
24
|
| |
*
|
Other income, net
|
| |
289
|
| |
736
|
| |
(447)
|
| |
*
|
Total other expense
|
| |
$(2,977)
|
| |
$(556)
|
| |
$(2,421)
|
| |
*
|
*
|
— % not meaningful
|
|
| |
Year ended December 31,
|
| |
Change
|
||||||
(dollars in thousands)
|
| |
2022
|
| |
2021
|
| |
$
|
| |
%
|
Income tax expense
|
| |
$ —
|
| |
$460
|
| |
$(460)
|
| |
—
|
*
|
— % not meaningful
|
|
| |
Year ended December 31,
|
| |
Change
|
||||||
(dollars in thousands)
|
| |
2021
|
| |
2020
|
| |
$
|
| |
%
|
Patient service revenue, net
|
| |
$938,242
|
| |
$714,678
|
| |
$223,564
|
| |
31.3%
|
HHS grant income
|
| |
—
|
| |
6,841
|
| |
(6,841)
|
| |
(100.0)%
|
Other revenue
|
| |
5,505
|
| |
3,224
|
| |
2,281
|
| |
70.8%
|
Total revenue
|
| |
$943,747
|
| |
$724,743
|
| |
$219,004
|
| |
30.2%
|
|
| |
Year ended December 31,
|
| |
Change
|
||||||
(dollars in thousands)
|
| |
2021
|
| |
2020
|
| |
$
|
| |
%
|
Cost of revenue
|
| |
$865,788
|
| |
$658,638
|
| |
$207,150
|
| |
31.5%
|
General and administrative expenses
|
| |
77,048
|
| |
44,033
|
| |
33,015
|
| |
75.0%
|
Total costs and expenses
|
| |
$942,836
|
| |
$702,671
|
| |
$240,165
|
| |
34.2%
|
|
| |
Year ended December 31,
|
| |
Change
|
||||||
(dollars in thousands)
|
| |
2021
|
| |
2020
|
| |
$
|
| |
%
|
Interest expense
|
| |
$(1,419)
|
| |
$(1,116)
|
| |
$(303)
|
| |
27.2%
|
Interest income
|
| |
127
|
| |
32
|
| |
95
|
| |
*
|
Other income, net
|
| |
736
|
| |
180
|
| |
556
|
| |
*
|
Total other expense
|
| |
$(556)
|
| |
$(904)
|
| |
$348
|
| |
(38.5)%
|
*
|
— % not meaningful
|
|
| |
Year ended December 31,
|
| |
Change
|
||||||
(dollars in thousands)
|
| |
2021
|
| |
2020
|
| |
$
|
| |
%
|
Income tax expense (benefit)
|
| |
$460
|
| |
$(783)
|
| |
$1,243
|
| |
(158.7)%
|
|
| |
Three Months
Ended September 30,
|
| |
Change
|
| |
Nine Months Ended
September 30,
|
| |
Change
|
||||||||||||
(dollars in thousands)
|
| |
2023
|
| |
2022
|
| |
$
|
| |
%
|
| |
2023
|
| |
2022
|
| |
$
|
| |
%
|
Net loss
|
| |
$(29,205)
|
| |
$5,607
|
| |
$(34,812)
|
| |
(620.9%)
|
| |
$(40,797)
|
| |
$1,227
|
| |
$(42,024)
|
| |
(3424.9%)
|
Interest expense, net
|
| |
1,159
|
| |
875
|
| |
284
|
| |
32.5%
|
| |
4,001
|
| |
1,930
|
| |
2,071
|
| |
107.3%
|
Depreciation and amortization
|
| |
2,060
|
| |
2,159
|
| |
(99)
|
| |
(4.6%)
|
| |
6,368
|
| |
5,318
|
| |
1,050
|
| |
19.7%
|
Income tax expense
|
| |
315
|
| |
—
|
| |
315
|
| |
*
|
| |
315
|
| |
—
|
| |
315
|
| |
*
|
Non-cash stock compensation
|
| |
4,875
|
| |
5
|
| |
4,870
|
| |
*
|
| |
4,875
|
| |
15
|
| |
4,860
|
| |
*
|
Operational transformation(a)
|
| |
—
|
| |
235
|
| |
(235)
|
| |
(100.0%)
|
| |
—
|
| |
1,409
|
| |
(1,409)
|
| |
(100.0)%
|
Gain/loss on derivative liabilities
|
| |
3,316
|
| |
—
|
| |
3,316
|
| |
*
|
| |
8,382
|
| |
—
|
| |
8,382
|
| |
*
|
Transaction expenses(b)
|
| |
24,603
|
| |
151
|
| |
24,452
|
| |
*
|
| |
29,886
|
| |
151
|
| |
29,735
|
| |
*
|
Adjusted EBITDA
|
| |
$7,123
|
| |
$9,032
|
| |
$(1,909)
|
| |
(21.1%)
|
| |
$13,030
|
| |
$10,050
|
| |
$2,980
|
| |
29.7%
|
*
|
— % not meaningful
|
(a)
|
Personnel costs associated with rationalization of our central services cost structure
|
(b)
|
Transaction expenses are one-time non-recurring and are a result of expenses incurred in connection with the Business Combination.
|
|
| |
Three Months
Ended September 30,
|
| |
Change
|
| |
Nine Months Ended
September 30,
|
| |
Change
|
||||||||||||
(dollars in thousands)
|
| |
2023
|
| |
2022
|
| |
$
|
| |
%
|
| |
2023
|
| |
2022
|
| |
$
|
| |
%
|
Net loss
|
| |
$(29,205)
|
| |
$5,607
|
| |
$(34,812)
|
| |
(620.9%)
|
| |
$(40,797)
|
| |
$1,227
|
| |
$(42,024)
|
| |
(3424.9%)
|
Plus: Non-cash stock compensation
|
| |
4,875
|
| |
5
|
| |
4,870
|
| |
*
|
| |
4,875
|
| |
15
|
| |
4,860
|
| |
*
|
Plus: Gain/loss on derivative liabilities
|
| |
3,316
|
| |
—
|
| |
3,316
|
| |
*
|
| |
8,382
|
| |
—
|
| |
8,382
|
| |
*
|
Plus: Transaction expenses(a)
|
| |
24,603
|
| |
151
|
| |
24,452
|
| |
*
|
| |
29,886
|
| |
151
|
| |
29,735
|
| |
*
|
Total Adjusted Net Income
|
| |
$3,589
|
| |
$5,763
|
| |
$(2,174)
|
| |
(37.7%)
|
| |
$2,346
|
| |
$1,393
|
| |
$953
|
| |
68.4%
|
*
|
— % not meaningful
|
(a)
|
Transaction expenses are one-time non-recurring and are a result of expenses incurred in connection with the Business Combination.
|
|
| |
Year Ended
December 31,
|
| |
Change
|
||||||
(dollars in thousands)
|
| |
2022
|
| |
2021
|
| |
$
|
| |
%
|
Net income
|
| |
$2,589
|
| |
$(105)
|
| |
$2,694
|
| |
*
|
Interest expense, net
|
| |
3,266
|
| |
1,292
|
| |
1,974
|
| |
152.8%
|
Depreciation and amortization
|
| |
6,719
|
| |
6,079
|
| |
640
|
| |
10.5%
|
Income tax expense (benefit)
|
| |
0
|
| |
460
|
| |
(460)
|
| |
(100.0)%
|
Non-cash stock compensation
|
| |
—
|
| |
20
|
| |
(20)
|
| |
(100.0)%
|
Insourcing transition expenses**
|
| |
—
|
| |
1,886
|
| |
(1,886)
|
| |
(100.0)%
|
Other***
|
| |
510
|
| |
—
|
| |
510
|
| |
100.0%
|
Operational transformation****
|
| |
1,726
|
| |
—
|
| |
1,726
|
| |
100.0%
|
Transaction costs
|
| |
3,277
|
| |
—
|
| |
3,277
|
| |
100.0%
|
Adjusted EBITDA
|
| |
$18,087
|
| |
$9,632
|
| |
$8,455
|
| |
87.8%
|
*
|
% not meaningful
|
**
|
These expenses relate to incremental costs associated with our transition from a third-party back- office service provider to
internal resources.
|
***
|
Costs incurred related to Hurricane Ian.
|
****
|
Personnel costs associated with rationalization of our central services cost structure.
|
|
| |
Year Ended December 31,
|
| |
Change
|
||||||
(dollars in thousands)
|
| |
2021
|
| |
2020
|
| |
$
|
| |
%
|
Net income
|
| |
$(105)
|
| |
$21,951
|
| |
$(22,056)
|
| |
(100.5)%
|
Interest expense, net
|
| |
1,292
|
| |
1,084
|
| |
208
|
| |
19.2%
|
Depreciation and amortization
|
| |
6,079
|
| |
3,656
|
| |
2,423
|
| |
66.3%
|
Income tax expense (benefit)
|
| |
460
|
| |
(783)
|
| |
1,243
|
| |
(158.8)%
|
Non-cash stock compensation
|
| |
20
|
| |
20
|
| |
—
|
| |
—
|
Insourcing transition expenses**
|
| |
1,886
|
| |
—
|
| |
1,886
|
| |
*
|
Adjusted EBITDA***
|
| |
$9,632
|
| |
$25,928
|
| |
$(16,296)
|
| |
(62.9)%
|
*
|
% not meaningful
|
**
|
These expenses relate to incremental costs associated with our transition from a third-party back-office service provider to
internal resources.
|
|
| |
Nine Months Ended
September 30,
|
| |
Change
|
||||||
(dollars in
thousands)
|
| |
2023
|
| |
2022
|
| |
$
|
| |
%
|
Net cash (used) provided by in operations
|
| |
$(6,160)
|
| |
$1,630
|
| |
$(7,790)
|
| |
(477.9)%
|
Net cash used in investing activities
|
| |
(24,673)
|
| |
(13,059)
|
| |
(11,614)
|
| |
88.9%
|
Net cash provided by financing activities
|
| |
55,560
|
| |
15,758
|
| |
39,802
|
| |
252.6%
|
•
|
The operating cash flows period over period were positively impacted by a $16.4 million improvement in net changes to working
capital components.
|
•
|
The impacts from changes in the Medicare advance payments liability, which had no impact on cash flows in the nine month period
ended September 30, 2023, but had a $3.7 negative impact in the nine-month period ended September 30, 2022.
|
•
|
These improvements above were offset by a $28.0 million reduction in cash provided by net loss including the effects of
non-cash reconciling items.
|
•
|
Purchases of marketable securities for the nine months ended September 30, 2023 of $20.8 million were offset by sales of
marketable securities of $4.9 million. Purchases of marketable securities for the nine months ended September 30, 2022 were $11.9 million offset by sales of $2.0 million during this period. This difference resulted in a $6.0 million
increase in cash used between periods.
|
•
|
The $4.5 million increase in purchases of property and equipment during the nine months ended September 30, 2023 compared to
2022 further increased the cash used between periods. Proceeds from disposals of property in the prior period of $1.1 million also contributed to the increase in cash used between periods.
|
Level 1
|
Inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.
|
Level 2
|
Inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived
valuations in which all significant inputs are observable for substantially the full term of the asset or liability.
|
Level 3
|
Inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability.
This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.
|